Form 6-K Celyad Oncology SA For: Feb 03
- Wall Street spikes as Fed hints at rate hike pause
- Fed Day: '25bps seems the most likely, and best outcome' - JPMorgan
- U.S. Fed delivers small rate hike amid global banking turmoil
- PacWest says it would not be 'prudent' to go ahead with capital raise
- Meme stocks rally after GameStop posts surprise fourth-quarter profit
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of February 2023
Commission File Number: 001-37452
CELYAD ONCOLOGY SA
(Translation of registrants name into English)
Rue Edouard Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F K ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Celyad Oncology SA
Financial and Operating Results
On February 3, 2023, Celyad Oncology SA (the Company) issued a press release announcing its financial and operating results for the fourth quarter of 2022. A copy of the Companys press release is attached hereto as Exhibit 99.1. Exhibit 99.1 is incorporated herein by reference.
The information contained in this Current Report on Form 6-K, including Exhibit 99.1, except for the quote of Michel Lussier contained in Exhibit 99.1, is hereby incorporated by reference into the Companys Registration Statements on Forms F-3 (File No. 333-248464) and S-8 (File No. 333-220737).
|99.1||Press release issued by the registrant on February 3, 2023|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|CELYAD ONCOLOGY SA|
|Date: February 3, 2023||
/s/ Michel Lussier
Interim Chief Executive Officer
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Celyad Oncology to announce full year 2022 financial results and host conference call
- BrillDog Founder Named SDCE Provider Pros to Know
- Nevada Legislators File Psilocybin, MDMA Legalization Measure
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!